Infectious Diseases Department, Dijon Bourgogne University Hospital , 14 rue Paul Gaffarel, 21079, Dijon, France.
Lipness team, INSERM Research Center LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France.
J Transl Med. 2020 Dec 3;18(1):457. doi: 10.1186/s12967-020-02646-9.
Although immune modulation is a promising therapeutic avenue in coronavirus disease 2019 (COVID-19), the most relevant targets remain to be found. COVID-19 has peculiar characteristics and outcomes, suggesting a unique immunopathogenesis.
Thirty-six immunocompetent non-COVID-19 and 27 COVID-19 patients with severe pneumonia were prospectively enrolled in a single center, most requiring intensive care. Clinical and biological characteristics (including T cell phenotype and function and plasma concentrations of 30 cytokines) and outcomes were compared.
At similar baseline respiratory severity, COVID-19 patients required mechanical ventilation for significantly longer than non-COVID-19 patients (15 [7-22] vs. 4 (0-15) days; p = 0.0049). COVID-19 patients had lower levels of most classical inflammatory cytokines (G-CSF, CCL20, IL-1β, IL-2, IL-6, IL-8, IL-15, TNF-α, TGF-β), but higher plasma concentrations of CXCL10, GM-CSF and CCL5, compared to non-COVID-19 patients. COVID-19 patients displayed similar T-cell exhaustion to non-COVID-19 patients, but with a more unbalanced inflammatory/anti-inflammatory cytokine response (IL-6/IL-10 and TNF-α/IL-10 ratios). Principal component analysis identified two main patterns, with a clear distinction between non-COVID-19 and COVID-19 patients. Multivariate regression analysis confirmed that GM-CSF, CXCL10 and IL-10 levels were independently associated with the duration of mechanical ventilation.
We identified a unique cytokine response, with higher plasma GM-CSF and CXCL10 in COVID-19 patients that were independently associated with the longer duration of mechanical ventilation. These cytokines could represent the dysregulated immune response in severe COVID-19, as well as promising therapeutic targets. ClinicalTrials.gov: NCT03505281.
尽管免疫调节是治疗 2019 年冠状病毒病(COVID-19)的一种有前途的方法,但仍需要找到最相关的目标。COVID-19 具有独特的特征和结果,表明其具有独特的免疫发病机制。
在一家单中心前瞻性纳入 36 例免疫功能正常的非 COVID-19 和 27 例 COVID-19 重症肺炎患者,大多数患者需要重症监护。比较临床和生物学特征(包括 T 细胞表型和功能以及 30 种细胞因子的血浆浓度)和结局。
在相似的基础呼吸严重程度下,COVID-19 患者需要机械通气的时间明显长于非 COVID-19 患者(15 [7-22] 天与 4 [0-15] 天;p=0.0049)。与非 COVID-19 患者相比,COVID-19 患者的大多数经典炎症细胞因子(G-CSF、CCL20、IL-1β、IL-2、IL-6、IL-8、IL-15、TNF-α、TGF-β)水平较低,但 CXCL10、GM-CSF 和 CCL5 的血浆浓度较高。与非 COVID-19 患者相比,COVID-19 患者的 T 细胞衰竭相似,但炎症/抗炎细胞因子反应更为失衡(IL-6/IL-10 和 TNF-α/IL-10 比值)。主成分分析确定了两种主要模式,非 COVID-19 和 COVID-19 患者之间存在明显差异。多变量回归分析证实 GM-CSF、CXCL10 和 IL-10 水平与机械通气时间独立相关。
我们发现了一种独特的细胞因子反应,COVID-19 患者的血浆 GM-CSF 和 CXCL10 水平较高,与机械通气时间较长独立相关。这些细胞因子可能代表严重 COVID-19 中失调的免疫反应,也是有前途的治疗靶点。ClinicalTrials.gov:NCT03505281。